The Associated Press published an article discussing a study on the Pfizer COVID-19 antiviral pill. While the pill did reduce the risk of hospitalization and death for high-risk seniors, it showed little effect for younger adults. This leaves Plaxlovid as the best option for people who remain at a high risk of severe COVID-19.

Dr. David Boulware in the Department of Medicine spoke to the Associated Press about a large study published showing Pfizer’s COVID-19 pill appears to provide little or no benefit for younger adults while still reducing the risk of hospitalization and death for high-risk seniors. “Paxlovid will remain important for people at the highest risk of severe COVID-19, such as seniors and those with compromised immune systems,” said Boulware. “But for the vast majority of Americans who are now eligible, this really doesn’t have a lot of benefits.” 

The article was republished by numerous outlets, including The Washington Post, The Los Angeles Times, and ABC News.

Read More >>>